COMP <GO>
INSM vs MRK // FORWARD P/E MULTIPLE
Insmed Incorporated (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: INSM 5
— MRK 9
▲ FORWARD P/E MULTIPLE LEADER: MRK
LAST: $112.58 (+0.89%) • MKT CAP: $24.37B
forward-pe
21.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INSM VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INSM | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.70% | 74.80% | +4.90 | INSM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.97% | 3.42% | -7.39 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 66.70% | 1.30% | +65.40 | INSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.25 | 5.19 | +0.06 | INSM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.60% | +0.40 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.7 | 56.9 | +5.87 | INSM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.03 | 0.92 | +0.11 | INSM | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 21.0x | 18.4x | +2.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.37B | $361.02B | -$336.65B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INSM REV | MRK REV | INSM GROSS % | MRK GROSS % | INSM FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $606.4M | $65.01B | 79.7% | 74.8% | -$967.6M | $12.36B |
| FY 2024 | $363.7M | $64.17B | 76.4% | 76.3% | -$705.8M | $18.10B |
| FY 2023 | $305.2M | $60.12B | 44.0% | 44.0% | -$550.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INSM // BETA 1.03
MRK // BETA 0.92